Osnovna hipoteza ovoga rada je pokušaj da se jasno dokaže izražajnost mucinoznog glikoproteina MUC 2 i vaskularnog endotelijalnog faktora rasta (VEGF) na sluznici oboljelih od Barrettovog jednjaka, te pokušaj dokazivanja povezanosti s izražajnošću ovih antigena u sve češćoj pojavnosti adenokarcinoma jednjaka na sluznici Barrettovog jednjaka. U izvornu je studiju uključeno 36 ispitanika s dijagnozom Barrettovog jednjaka, nakon prve ezofagogastroduodenoskopije, ali je nakon patološke analize bioptata ezofagogastričnog spoja u četvoro ispitanika dokazan adenokarcinom. Izražajnost MUC 2 i VEGF-a, određena je imunohistokemijskom analizom. MUC 2 bio je pozitivan u troje ispitanika s adenokarcinomom, a VEGF također u troje, što daje naslutiti da angiogeneza ima važnu ulogu u zamjeni normalne sluznice jednjaka s Barrettovom sluznicom.The aim of this study was to evaluate the expression of Mucin 2 glycoprotein (MUC2) and Vascular Endothelial Growth Factor (VEGF) in Barrett’s mucosa in association with higher risk for the development of adenocarcinoma (AC). The study included a group of 36 patients with diagnosis of Barrettʹs esophagus (BE) after esophagogastroduodenoscopy, but the pathohistological analysis of esophagogastric junction (EGJ) mucosa showed adenocarcinoma in four patients. The expression of MUC2 and VEGF was performed with immunohistochemistry. MUC2 was expressed in three patients, and VEGF expression was present at three patients in the study, which suggested that angiogenesis could have an important role in replacing normal esophageal mucosa with Barrett’s mucosa
